Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sareum Holdings PLC (GB:SAR)
LSE:SAR
Holding GB:SAR?
Track your performance easily
SAR Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range10.00p - 78.00p
Previous Close24.75p
Volume566.47K
Average Volume (3M)286.79K
Market Cap
£30.87M
Enterprise Value29.88M
Total Cash (Recent Filing)£994.00K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Mar 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding107,950,000
10 Day Avg. Volume305,072
30 Day Avg. Volume286,790
Standard Deviation0.45
R-Squared0.00956
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Sareum Holdings News
PremiumCompany Announcements
Sareum Holdings Advances in Autoimmune and Cancer Drug Development
PremiumCompany Announcements
Sareum Holdings Secures Additional Funding for Drug Development
PremiumCompany Announcements
Sareum Holdings Secures Funds for Phase 2 Trials
PremiumCompany Announcements
Sareum Holdings Bolsters Patent Portfolio in ChinaPremiumCompany Announcements
Sareum Holdings Secures US Patent for Autoimmune Therapy
PremiumCompany Announcements
Sareum Holdings Announces Executive Reshuffle
PremiumCompany Announcements
Sareum Holdings Reports Promising Phase 1 ResultsPremiumCompany Announcements
Sareum Holdings Appoints New Sole BrokerOptions Prices
Currently, No data available
---
Ownership Overview
SAR FAQ
What was Sareum Holdings PLC’s price range in the past 12 months?
Sareum Holdings PLC lowest share price was 10.00p and its highest was 78.00p in the past 12 months.
What is Sareum Holdings PLC’s market cap?
Currently, no data Available
When is Sareum Holdings PLC’s upcoming earnings report date?
Sareum Holdings PLC’s upcoming earnings report date is Mar 27, 2025 which is in 125 days.
How were Sareum Holdings PLC’s earnings last quarter?
Sareum Holdings PLC released its earnings results on Oct 29, 2024. The company reported -0.008p earnings per share for the quarter, missing the consensus estimate of N/A by -0.008p.
Is Sareum Holdings PLC overvalued?
According to Wall Street analysts Sareum Holdings PLC’s price is currently Overvalued.
Does Sareum Holdings PLC pay dividends?
Sareum Holdings PLC does not currently pay dividends.
What is Sareum Holdings PLC’s EPS estimate?
Sareum Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sareum Holdings PLC have?
Sareum Holdings PLC has 124,746,340 shares outstanding.
What happened to Sareum Holdings PLC’s price movement after its last earnings report?
Sareum Holdings PLC reported an EPS of -0.008p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6%.
Which hedge fund is a major shareholder of Sareum Holdings PLC?
Currently, no hedge funds are holding shares in GB:SAR
---
Sareum Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.95%
12-Months-Change
Fundamentals
Return on Equity
-209.37%
Trailing 12-Months
Asset Growth
36.98%
Trailing 12-Months
Company Description
Sareum Holdings PLC
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase program focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders.
---
Technical Analysis
---